What is the price of Bimetinib/Bemetinib in India?

Binimetinib/Binimetinib is a targeted therapy drug mainly used to treat specific types of melanoma and other malignant tumors. Its indications mainly include BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma and non-small cell lung cancer . BRAF mutations are spontaneous changes in the BRAF gene that prevent it from working properly, meaning that certain cells receive constant signals to continue dividing, leading to the development of tumors. It is administered together with Encorafenib, which targets different kinases in the RAS/RAF/MEK/ERK pathway. Studies have shown that bimetinib, when used in combination with it, can significantly improve treatment effects and prolong patient survival.

In terms of production, the original drug of bimetinib has not yet been put on the Chinese market, so it has not been included in the medical insurance system, and the price information is relatively vague. However, bimetinib can already be found on the international market, especially in Europe. The common specification is 15mg, and each box contains 84 or 168 tablets. The price may be as high as 20,000 yuan, and the specific price will change due to exchange rate fluctuations.

With the progress of drug research and development, generic drugs of bimetinib have appeared on the market. In Laos, Lucius Pharmaceuticals launched the first generic version of bimetinib, which has similar ingredients to the original drug, providing more choices. Although Indian pharmaceutical companies have not yet produced original or generic versions of bimetinib, the drug may enter the Indian market through imports. This provides Indian patients with access to the drug, especially when faced with the high cost of treatment.

In the Lao market, if generic versions of bimetinib are available, patients will be able to receive treatment at a relatively low cost. For example, the specification is 15mg*180 tablets, and the price per box is about more than 6,000 yuan, which provides a more feasible treatment option for patients with limited financial conditions.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi